Evidence map›Paper›PMID 25956795›Full record

Trial reportThe Lancet. Oncology2015

Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.

Alexandria T Phan, Daniel M Halperin, Jennifer A Chan, David R Fogelman, Kenneth R Hess, Paige Malinowski, Eileen Regan, Chaan S Ng, James C Yao, Matthew H Kulke

Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Lancet. Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00454363 (A Phase 2 Study of GW786034), which is not on this map. Cited by 61 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 3 pooled it
12.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00454363 phase2completednot on this map

A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma

TypeinterventionalSponsorNational Cancer Institute (NCI)Ran2007 to 2014Enrolled52ConditionsGastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Multiple Endocrine Neoplasia Type 1ArmsLaboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study
3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 3 syntheses or guidelines pooled it, 122 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Trial
  5. Trial
  6. Trial
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Alexandria T PhanDepartment of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Daniel M HalperinDepartment of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jennifer A ChanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
David R FogelmanDepartment of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kenneth R HessDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Paige MalinowskiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Eileen ReganDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Chaan S NgDepartment of Diagnostic Radiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
James C YaoDepartment of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: jyao@mdanderson.org.
Matthew H KulkeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
The University of Texas MD Anderson Cancer Center · USDana-Farber Cancer Institute · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS HHSN261201100039CNCI NIH HHS N01CM-2011-00039NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

backgroundTreatment options for advanced, well-differentiated neuroendocrine tumours (NETs) remain scarce. Pazopanib is an orally bioavailable, small molecule, multitargeted kinase inhibitor that inhibits VEGF receptors 1, 2, and 3. We did a study of the efficacy of pazopanib with depot octreotide in patients with advanced NETs.

methodsWe did a parallel cohort study of patients with metastatic or locally advanced grade 1-2 carcinoid tumours or pancreatic NETs, by use of a single-group, two-stage design. Patients received pazopanib 800 mg orally once per day and octreotide at their preprotocol dosage. The primary endpoint was the proportion of patients achieving an objective response, as assessed by investigators, by intention-to-treat analysis. This study is registered with ClinicalTrials.gov, identifier NCT00454363, and was completed in March, 2014.

findingsBetween April 12, 2007, and July 2, 2009, we enrolled 52 patients, including 32 individuals with pancreatic NETs and 20 individuals with carcinoid tumours. Seven (21·9%, 95% CI 11·0-38·8) of 32 patients with pancreatic NETs achieved an objective response. We detected no responses in the first stage of the cohort with carcinoid tumours, and we terminated accrual at 20 patients. Toxic effects included one patient with grade 4 hypertriglyceridaemia and one with grade 4 thrombosis, with the most common grade three events being aminotransferase increases and neutropenia, each of which happened in 3 patients. In all 52 patients, the most frequently observed toxic effects were fatigue (39 [75%]), nausea (33 [63%]), diarrhoea (33 [63%]), and hypertension (28 [54%]).

interpretationTreatment with pazopanib is associated with tumour response for patients with pancreatic NETs, but not for carcinoid tumours; a randomised controlled phase 3 study to assess pazopanib in advanced pancreatic NETs is warranted.

fundingUS National Cancer Institute of the National Institutes of Health.

Indexed as

AgedCarcinoid TumorCohort StudiesDisease-Free SurvivalFemaleHumansIndazolesMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingNeuroendocrine TumorsPancreatic NeoplasmsPyrimidinesReceptors, Vascular Endothelial Growth FactorSulfonamidesIndazolespazopanibPyrimidinesReceptors, Vascular Endothelial Growth FactorSulfonamides

Identifiers

PMID25956795
PMCPMC4800487
OpenAlexW2104658769

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.